Mutation status of refractory to imatinib patients with chronic myeloid leukemia by E. G. Ovsyannikova, K. D. Kaplanov, T. Yu. Klitochenko, A. V. Misyurin, I. L. Davydkin, L. V. Zaklyakova, E. A. Popov, B. N. Levitan

Subjects: Get full text

Erratum to: Imatinib relaxes the pulmonary venous bed of guinea pigs by Nina A. Maihöfer, Said Suleiman, Daniela Dreymüller, Paul W. Manley, Rolf Rossaint, Stefan Uhlig, Christian Martin, Annette D. Rieg

Get full text

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib by Richard Quek, Suzanne George

“…In addition, the role of imatinib in localized GIST has gained much interest and may improve patient outcomes. …”
Get full text

Combination Therapy With Rapamycin and Low Dose Imatinib in Pulmonary Hypertension by Yinan Shi, Yinan Shi, Chenxin Gu, Tongtong Zhao, Yangfan Jia, Changlei Bao, Changlei Bao, Ang Luo, Qiang Guo, Ying Han, Jian Wang, Stephen M. Black, Stephen M. Black, Ankit A. Desai, Haiyang Tang, Haiyang Tang

Subjects: Get full text

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor by Wen-Kuan Huang, Jiwei Gao, Ziqing Chen, Hao Shi, Juan Yuan, Huanhuan L. Cui, Chun-Nan Yeh, Robert Bränström, Catharina Larsson, Shuijie Li, Weng-Onn Lui

Subjects: Get full text

Defining the target and the effect of imatinib on the filarial c-Abl homologue. by Elise M O'Connell, Olena Kamenyeva, Sara Lustigman, Aaron Bell, Thomas B Nutman

“…Previously we demonstrated the micro- and macrofilaricidal properties of imatinib in vitro. Here we use electron and multiphoton microscopy to define the target of imatinib in the adult and microfilarial stages of Brugia malayi and assess the effects of pharmacologically relevant levels of imatinib on the adult parasites.After fixation of adult B. malayi males and females, sections were stained with polyclonal rabbit anti-c-Abl antibody (or isotype control) and imaged with multiphoton fluorescent microscopy. …”
Get full text

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice by A. K. Golenkov, L. L. Vysotskaya, E. V. Trifonova, T. A. Mitina, T. D. Lutskaya, E. V. Kataeva, G. A. Dudina, Yu. B. Chernykh, I. V. Buravtsova, A. N. Gurov, R. V. Gorenkov

Subjects: Get full text

Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach by Pizzolato Nicola, Valenti Davide, Adorno Dominique, Spagnolo Bernardo

Get full text

Salvage therapy of imatinib-resistant hypereosinophilic syndrome with PDGFRB rearrangement by Miao-Erh Chang, Hao-Wei Teng

Subjects: Get full text

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors by Lei Cao, Lei Cao, Kunming Zheng, Kunming Zheng, Yanhong Liu, Yanhong Liu, Peng Song, Peng Song, Chuntao Wang, Chuntao Wang, Hongzhi Wang, Hongzhi Wang, Nan Wang, Nan Wang, Shiwu Zhang, Shiwu Zhang, Yongjie Zhao, Yongjie Zhao

Subjects: Get full text

Imatinib enhances functional outcome after spinal cord injury. by Mathew B Abrams, Ingrid Nilsson, Sebastian A Lewandowski, Jacob Kjell, Simone Codeluppi, Lars Olson, Ulf Eriksson

“…We investigated whether imatinib (Gleevec®, Novartis), a tyrosine kinase inhibitor, could improve functional outcome in experimental spinal cord injury. …”
Get full text

BIRC6 mediates imatinib resistance independently of Mcl-1. by Denis O Okumu, Michael P East, Merlin Levine, Laura E Herring, Raymond Zhang, Thomas S K Gilbert, David W Litchfield, Yanping Zhang, Lee M Graves

“…Our phosphoproteomic analysis of an imatinib-resistant chronic myelogenous leukemia (CML) cell line (MYL-R) identified increased amounts of a BIRC6 peptide phosphorylated at S480, S482, and S486 compared to imatinib-sensitive CML cells (MYL). …”
Get full text

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia by Alexandra Rodrigues Alves, William Gustavo Lima, Michelly Martins Nagai, João Paulo Vilela Rodrigues, Lorena Rocha Ayres

Subjects: Get full text

Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies by Michael R. Burgess, Charles L. Sawyers

“…Imatinib (Gleevec/STI-571/CGP57148B, Novartis) is a small-molecule, tyrosine kinase inhibitor developed to target BCR-ABL, c-Kit, and PDGF-R. …”
Get full text

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor. by Lori Rink, Michael F Ochs, Yan Zhou, Margaret von Mehren, Andrew K Godwin

“…Although imatinib mesylate (IM) has transformed the treatment of gastrointestinal stromal tumors (GIST), many patients experience primary/secondary drug resistance. …”
Get full text

Mutation status of refractory to imatinib patients with chronic myeloid leukemia by E. G. Ovsyannikova, K. D. Kaplanov, T. Yu. Klitochenko, A. V. Misyurin, I. L. Davydkin, L. V. Zaklyakova, E. A. Popov, B. N. Levitan

Subjects: Get full text

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE by Marjana Glaser, Tatjana Grmek Zemljič, Peter Borin

Subjects: Get full text

Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor by Gang Wang, Ning Zhuo, Ying Luo, Jie Li

Get full text

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice by A. K. Golenkov, L. L. Vysotskaya, E. V. Trifonova, T. A. Mitina, T. D. Lutskaya, E. V. Kataeva, G. A. Dudina, Yu. B. Chernykh, I. V. Buravtsova, A. N. Gurov, R. V. Gorenkov

Subjects: Get full text

Imatinib use in the management of a patient with Doege–Potter syndrome by Jose Paz-Ibarra, Jose Lu-Antara, Brenda-Erendida Uscamayta, Jhancy Martinez-Auris, Miriam Valencia-Rivera, Sofía Sáenz-Bustamante, Marialejandra Delgado-Rojas, Julia Salcedo-Vasquez, Marcio Concepción-Zavaleta

“…In this report, we present the case of a 67-year-old male with recurrent and refractory hypoglycemia due to DPS successfully treated with imatinib. He initially presented with neuroglycopenic symptoms and dyspnea secondary to a giant tumor in the left hemithorax, which was totally resected. …”
Get full text